Sharon E DEPARTMENT OF COMMERCE Application No. Docket No. 50623.351 10/807.362 gitally sign NF BRMATION BURE CITATION Applicant Thierry Glauser et al. nnegy N: cn=Sharon E. Kennedy, c=US in an Application USPTO, ou=1615, emailésharon.kennedy@uspto.go(Use several sheets if necessary) Date: 2007.12.21 01:21:33 -05'00' Group Art Unit Filing Date March 22, 2004 1615 **U.S. PATENT DOCUMENTS** Examiner Ref. No. Date of Class Subclass Filling Date if Document Name Appropriate Initial Number **Patent** 6,270,788 8/7/01 Koulik et al. /SK/A1 A2 А3 Α4 U.S. PATENT APPLICATION PUBLICATION DOCUMENTS Class Subclass Filing Date if Examiner Ref. No. **Document** Date of Name **Appropriate** Initial Number **Publication** 2005/0169957 8/4/05 Hossainy **A1** /SK/ **FOREIGN PATENT DOCUMENTS** Subclass Translation Examiner Ref. No. Class **Document** Date of Country Yes **Publication** Initial Number **EPO B**1 EP 0 947 205 10/6/99 /SK/ 7/26/01 **PCT** B2 WO 01/52915 /SK/ 10/25/01 PCT **B3** WO 01/78800 /SK/ 5/23/02 **PCT B4** WO 02/40558 /SK/ WO 03/022324 3/20/03 **PCT B**5 /SK/ **PCT** 3/18/04 B6 WO 2004/021976 /SK/ **B**7 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) International Search Report and Written Opinion of a PCT/US2005/008844, filed 3/17/05, mailed 9/13/05. **C**1 /SK/ Berrocal et al., "Improving the Blood Compatibility of Ion-Selective Electrodes by Employing Poly(MPC-co-C2 /SK/ BMA), a Copolymer Containing Phosphorylcholine, as a Membrane Coating", Hilborn et al., "Biodegradable Phosphatidylcholine Functional Poly (E-Caprolactone)", Pol. Mat. Science C3 /SK/ and Eng. Vol. 88, 2003, pp.109-110. Iwasaki, "Molecular Design and Preparation of Bioinspired Phospholipid Polymer as Novel Biomaterials", /SK/ Polymer Preprints, Soc. of Polymer Science, vol. 42, no. 2, 2001, pp. 117-118. Li et al., "Synthesis and Hemocompatibility Evaluation of Novel Segmented Polyurethanes with Phosphatidylcholine Polar Headgroups", Chemistry of Materials 10, American Chemical Society, 1998, pp. /SK/ 1596-1603.

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

12/21/2007

/Sharon Kennedy/

EXAMINER

Kennedy US-DEPARTMENT OF COMMERCE Application No. FORM PTO-1449 (Modified) Docket No. o=USPTO: US Patent and Trademark Office 10/807,362 Approved Bruse through 10/31/200'. 50623.351 INFORMATION DISCLETE CITATION in an Application Applicant Glauser et al. Date: 2007.12.21 JUL 1 2 2004 Group Art Unit Filing Date 1615 March 22, 2004 **U.S. PATENT DOCUMENTS** TRADE Class Subclass Filing Date If Name Date of **Document Appropriate Patent** Initial Number Joh 428 36 7/21/80 5/11/82 4,329,383 **A1** /SK/ 536 20 2/8/83 **A2** 9/23/86 Larm 4,613,665 11/7/85 128 343 **A3** 4,733,665 3/29/88 Palmaz 3/13/87 128 343 1/31/89 Gianturco Α4 4,800,882 424 468 9/5/86 Casey et al. Α5 11/21/89 4,882,168 10/19/87 343 12/12/89 Wiktor 128 **A6** 4,886,062 8/1/88 525 413 4/10/90 Tang et al. Α7 4,916,193 600 36 12/30/88 Α8 4,941,870 7/17/90 Okada et al. 772 4/6/90 128 Ofstead **A9** 4,977,901 12/18/90 194 5/22/89 2/19/91 MacGregor 606 4,994,071 A10 623 1 7/5/90 **Pinchuk** 3/3/92 A11 5,092,877 7/23/90 204 165 5/12/92 Marchant A12 5,112,457 9/14/90 11/17/92 Froix 623 1 A13 5,163,952 424 488 9/26/90 Sasaki et al. 11/24/92 5,165,919 A14 523 112 6/17/91 Winters et al. A15 5,182,317 1/26/93 11/16/93 Winters et al. 523 112 7/5/88 5,262,451 A16 423.1 1/29/92 428 Opolski A17 5,272,012 12/21/93 423 11/8/91 424 A18 5,292,516 3/8/94 Viegas et al. 6/9/92 424 486 A19 5,298,260 3/29/94 Viegas et al. 424 427 9/13/91 Viegas et al. A20 5,300,295 4/5/94 604 53 11/22/91 4/19/94 Sahatjian A21 5,304,121 423 11/8/91 424 **A22** 5,306,501 4/26/94 Viegas et al. 604 101 8/4/93 **A23** 7/12/94 Slepian 5,328,471 501 7/5/91 424 7/19/94 Park et al. **A24** 5,330,768 112 4/12/90 8/16/94 Winters et al. 523 A25 5,338,770

1/10/95

604

Fearnot et al.

265

8/30/93

**A26** 

5,380,299

<del></del>	1			<b>-</b>	100	400	4/00/00
/SK/	A27	5,417,981	5/23/95	Endo et al.	424	486	4/28/93
	A28	5,447,724	9/5/95	-Helmus et al.	424	426	11/15/93
_	A29	5,455,040	10/3/95	Marchant	424	426	11/19/92
	A30	5,462,990	10/31/95	Hubbell et al.	525	54.1	10/5/93
	A31	5,464,650	11/7/95	Berg et al.	427	2.30	4/26/93
	A32	5,569,463	10/29/96	Helmus et al.	424	426	6/7/95
	A33	5,578,073	11/26/96	Haimovich et al.	623	1	9/16/94
_	A34	5,605,696	2/25/97	Eury et al.	424	423	3/30/95
	A35	5,609,629	3/11/97	Fearnot et al.	623	1	6/7/95
	A36	5,624,411	4/29/97	Tuch	604	265	6/7/95
	A37	5,628,730	5/13/97	Shapland et al.	604	21	7/18/94
	A38	5,649,977	7/22/97	Campbell	623	1	9/22/94
	A39	5,658,995	8/19/97	Koḥn et al.	525	432	11/27/95
	A40	5,667,767	9/16/97	Greff et al.	424	9.411	7/27/95
	A41	5,670,558	9/23/97	Onishi et al.	523	112	7/6/95
	A42	5,679,400	10/21/97	Tuch	427	2.14	6/7/95
	A43	5,700,286	12/23/97	Tartaglia et al.	623	1	8/22/96
	A44	5,702,754	12/30/97	Zhong	427	2.12	2/22/95
	A45	5,716,981	2/10/98	Hunter et al.	514	449	6/7/95
	A46	5,735,897	4/7/98	Buirge	623	12	1/2/97
	A47	5,746,998	5/5/98	Torchilin et al.	424	9.4	8/8/96
	A48	5,776,184	7/7/98	Tuch	623	1	10/9/96
	A49	5,788,979	8/4/98	Alt et al.	424	426	2/10/97
	A50	5,800,392	9/1/98	Racchini ·	604	- 96	5/8/96
	A51	5,820,917	10/13/98	Tuch	427	2.1	6/7/95
	A52	5,824,048	10/20/98	Tuch	623	1	10/9/96
	A53	5,824,049	10/20/98	Ragheb et al.	623	1	10/31/96
	A54	5,830,178	11/3/98	Jones et al.	604	49	10/11/96
	A55	5,837,008	11/17/98	Berg et al.	623	1	4/27/95
	A56	5,837,313	11/17/98	Ding et al.	427	2.21	6/13/96
1	A57	5,851,508	12/22/98	Greff et al.	424	9.411	2/14/97
/SK/	A58	5,858,746	1/12/99	Hubbell et al.	435	177	1/25/95

/SK/	A59	5,865,814	2/2/99	Tuch	604	265	8/6/97
1	A60	5,869,127	2/9/99	Zhong	427	2.12	6/18/97
	A61	5,873,904	2/23/99	Ragheb et al.	623	1	2/24/97
	A62	5,876,433	3/2/99	Lunn	623	1	5/29/96
	A63	5,877,224	3/2/99	Brocchini et al.	514	772.2	7/28/95
	A64	5,925,720	7/20/99	Kataoka et al.	525	523	12/18/97
	A65	5,955,509	9/21/99	Webber et al.	514	772.7	4/23/97
	A66	5,971,954	10/26/99	Conway et al.	604	96	1/29/97
1-	A67	5,980,928	11/9/99	Terry	424	427	7/29/97
	A68	5,980,972	11/9/99	Ding	427	2.24	9/22/97
	A69	5,997,517	12/7/99	Whitbourne	604	265	1/27/97
	A70	6,010,530	1/4/00	Goicoechea	623	1	2/18/98
	A71	6,015,541	1/18/00	Greff et al.	424	1.25	11/3/97
	A72	6,033,582	3/7/00	Lee et al.	216	37	1/16/98
	A73	6,042,875	3/28/00	Ding et al.	427	2.24	3/2/99
	A74	6,051,648	4/18/00	Rhee et al.	525	54.1	1/13/99
	A75	6,051,576	4/18/00	Ashton et al.	514	255	1/29/97
	A76	6,056,993	5/2/00	Leidner et al.	427	2.25	4/17/98
	A77	6,060,451	5/9/00	DiMaio et al.	514	13	3/20/95
	A78	6,060,518	5/9/00	Kabanov et al.	514	781	8/16/96
	A79	6,080,488	6/27/00	Hostettler et al.	428	423.3	3/24/98
	A80	6,096,070	8/1/00	Ragheb et al.	623	1	5/16/96
	A81	6,099,562	8/8/00	Ding et al.	623	1.46	12/22/97
	A82	6,110,188	8/29/00	Narciso, Jr.	606	153	3/9/98
	A83	6,110,483	8/29/00	Whitbourne et al.	424	423	6/23/97
	A84	6,113,629	9/5/00	Ken	623	1.1	5/1/98
	A85	6,120,536	9/19/00	Ding et al.	623	1.43	6/13/96
	A86	6,120,904	9/19/00	Hostettler et al.	428	423.3	5/24/99
	A87	6,121,027	9/19/00	Clapper et al.	435	180	8/15/97
	A88	6,129,761	10/10/00	Hubbell	623	11	6/7/95
V	A89	6,153,252	11/28/00	Hossainy et al.	427	2.3	4/19/99
/SK/	A90	6,165,212	12/26/00	Dereume et al.	623	1.13	6/28/99

•				·			
/SK/	A91	6,203,551	3/20/01	Wu	606	108	10/4/99
	A92	6,231,600	5/15/01	Zhong	623	1.42	5/26/99
	A93	6,240,616	6/5/01	Yan	29	527.2	4/15/97
	A94	6,245,753	6/12/01	Byun et al.	514	56	4/27/99
	A95	6,251,136	6/26/01	Guruwaiya et al.	623	1.46	12/8/99
-   -	A96	6,254,632	7/3/01	Wu et al.	623	1.15	9/28/00
	A97	6,258,121	7/10/01	Yang et al.	623	1.46	7/2/99
	A98	6,283,947	9/4/01	Mirzaee	604	264	7/13/99
	A99	6,283,949	9/4/01	Roorda	604	288.02	12/27/99
	A100	6,284,305	9/4/01	Ding et al.	427	2.28	5/18/00
	A101	6,287,628	9/11/01	Hossainy et al.	427	2.3	9/3/99
	A102	6,299,604	10/9/01	Ragheb et al.	604	. 265	8/20/99
	A103	6,306,176	10/23/01	Whitbourne	623	23.59	9/21/99
	A104	6,331,313	12/18/01	Wong et al.	424	427	10/22/99
	A105	6,335,029	1/1/02	Kamath et al.	424	423	12/3/98
	A106	6,346,110	2/12/02	Wu	606	108	1/3/01
	A107	6,358,556	3/19/02	Ding et al.	427	2.24	1/23/98
	A108	6,379,381	4/30/02	Hossainy et al.	623	1.42	9/3/99
	A109	6,395,326	5/28/02	Castro et al.	427	2.24	5/31/00
	A110	6,419,692	7/16/02	Yang et al.	623	1.15	2/3/99
	A111	6,451,373	9/17/02	Hossainy et al.	427	2.25	8/4/00
	A112	6,494,862	12/17/02	Ray et al.	604	96.01	12/30/99
	A113	6,503,556	1/7/03	Harish et al.	427	2.24	12/28/00
	A114	6,503,954	1/7/03	Bhat et al.	514	772.2	7/21/00
	A115	6,506,437	1/14/03	Harish et al.	427	2.25	10/17/00
	A116	6,527,801	3/4/03	Dutta	623	1.46	4/13/00
	A117	6,527,863	3/4/03	Pacetti et al.	118	500	6/29/01
$\overline{\mathbf{V}}$	A118	6,540,776	4/1/03	Sanders Millare et al.	623	1.15	12/28/00
/SK/	A119	6,544,223	4/8/03	Kokish	604	103.01	1/5/01

/SK/	A120	6,544,543	4/8/03	Mandrusov et al.	424	422	12/2	7/00
	A121	6,544,582	4/8/03	Yoe	427	2.24	1/5	/01
	A122	6,555,157	4/29/03	Hossainy	427	2.24	7/25	5/00
<del>-  </del>	A123	6,558,733	5/6/03	Hossainy et al.	427	2.24	10/2	6/00
	A124	6,565,659	5/20/03	Pacetti et al.	118	500	6/28	3/01
_	A125	6,572,644	6/3/03	Moein	623	1.11	6/27	7/01
	A126	6,585,765	7/1/03	Hossainy et al.	623	1.45	6/29	9/00
1	A127	6,585,926	7/1/03	Mirzaee	264	400	8/31	/00
/SK/	A128	6,605,154	8/12/03	Villareal	118	500	5/31	/01
7010		U.S. PATE	NT APPLICAT	ION PUBLICATION DOCU	MENTS			
Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Appro	
/SK/	A129	2001/0018469	8/30/01	Chen et al.	523	121	12/2	
	A130	2001/0037145	11/1/01	Guruwaiya et al.	623	1.15	6/21	/01
	A131	2002/0077693	6/20/02	Barclay et al.	623	1.13	12/1	9/00
	A132	2002/0091433	7/11/02	Ding et al.	623	1.2	12/1	7/01
	A133	2002/0155212	10/24/02	Hossainy	427	2.25	4/24	1/01
V	A134	2003/0065377	4/3/03	Davila et al.	623	1.13	4/30	/02
/SK/	A135	2003/0099712	5/29/03	Jayaraman	424	486	11/2	6/01
			FOREIGN PA	ATENT DOCUMENTS				•
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation Yes N	
/SK/	B1	EP 0 301 856	2/1/89	European			-	
	B2	EP 0 514 406	11/25/92	European				
	В3	EP 0 604 022	6/29/94	European				
	B4	EP 0 623 354	11/9/94	European				
	<b>B</b> 5	EP 0 665 023	8/2/95	European				
	B6	EP 0 701 802	3/20/96	European				
	B7	EP 0 716 836	6/19/96	European				
	B8	EP 0 809 999	12/3/97	European				
	В9	EP 0 832 655	4/1/98	European				
	B10	EP 0 850 651	7/1/98	European				
V	B11	EP 0 879 595	11/25/98	European				<u> </u>
./SK/	B12	EP 0 910 584	4/28/99	European				

/SK/	B13	EP 0 923 953	6/23/99	European				
	B14	EP 0 953 320	11/3/99	European		<u> </u>		
	B15	EP 0 970 711	1/12/00	European			_	
	B16	EP 0 982 041	3/1/00	European				
	B17	EP 1 273 314	1/8/03	European				
	B18	2001-190687	7/17/01	Japan (Abstract)			Х	
	B19	WO 91/12846	9/5/91	PCT				
	B20	WO 95/10989	4/27/95	PCT				
	B21	WO 96/40174	12/19/96	PCT				
	B22	WO 97/10011	3/20/97	PCT				
	B23	WO 97/45105	12/4/97	PCT				
	B24	WO 97/46590	12/11/97	PCT				
	B25	WO 98/17331	4/30/98	PCT				
	B26	WO 98/36784	8/27/98	PCT				
	B27	WO 99/01118	1/14/99	PCT				
	B28	WO 99/38546	8/5/99	PCT				
	B29	WO 99/63981	12/16/99	PCT				
	B30	WO 00/02599	1/20/00	PCT				
	B31	WO 00/12147	3/9/00	PCT				
	B32	WO 00/18446	4/6/00	PCT				
	В33	WO 00/64506	11/2/00	PCT				
	B34	WO 01/01890	1/11/01	PCT				
	B35	WO 01/15751	3/8/01	PCT				
	B36	WO 01/17577	3/15/01	PCT				
	B37	WO 01/45763	6/28/01	PCT				
	B38	WO 01/49338	7/12/01	PCT				
	B39	WO 01/74414	10/11/01	PCT				
	B40	WO 02/03890	1/17/02	PCT				
, ] .	B41	WO 02/026162	4/4/02	PCT				
V	B42	WO 02/34311	5/2/02	PCT				
/SK/	B43	WO 02/056790	7/25/02	PCT		I		

									<del></del>		
/SK	/ B4	4	WO 03/000308	1/3/03	PCT				_	$\perp$	
/Sł	⟨/ B4	5	WO 03/022323	3/20/03	PCT						
/SK	(/ B4	6	WO 03/028780	4/10/03	PCT					_	
/SK	/ B4	7	WO 03/037223	5/8/03	PCT				_	_ _	
/SK	IJ <b>В</b> 4	8	WO 03/039612	5/15/03	PCT			1			
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)										
/SK	·/ C1		Anonymous, <i>Cardiolo</i> http://www.dialogweb	gists Draw - Up T .com/cqi/documer	he Dream Stent, Clinica 710: ht?reg=1061848202959, prin	15 (June 1 ted 8/25/03	17, 19 3 (2 pa	96), ages).		<u>-</u>	
	C2	2	Anonymous, <i>Heparin</i> - http://www.dialogweb	coated stents cut com/cgi/documer	complications by 30%, Clinic t?reg=1061847871753, print	ca 732:17 ted 8/25/0	(Nov. 3 (2 pa	18, 19 ages).	96), 		
	C3	3	Anonymous, <i>Rolling</i> 7 (Abstract 434009), Re		Loading Device for Therape 4-975 (June 2000).	utic Agent	Deliv	ery or	Coated	Sten	t
	C4	1	Anonymous, Stenting http://www.dialogweb	continues to dom	inate cardiology, Clinica 720 tt?req=1061848017752, prin	:22 (Sept. ted 8/25/0	2, 199 3 (2 pa	96), ages).	_		
	C5		Aoyagi et al., <i>Prepara</i> Journal of Controlled		d aliphatic polyester and app (1994).	olication to	therm	no-resp	onsive	mate	rial,
	C6		Barath et al., Low Do		gents Prevents Smooth Musc eb. 1989).	cle Cell Pro	oliferat	tion Aft	ter End	otheli	al
	C7		Barbucci et al., <i>Coatii</i> Mater. Res. 25:1259-		v available materials with a n	ew heparii	nizable	e mate	<i>rial</i> , J. E	Biome	ed.
	С8		Chung et al., Inner core segment design for drug delivery control of thermo-responsive polymeric micelles Journal of Controlled Release 65:93-103 (2000).								lles,
	C9	9	Dev et al., Kinetics of Comparative Study or	Drug Delivery to to fifther the Two Drugs, Cath	he Arterial Wall Via Polyuret eterization and Cardiovascu	hane-Coal lar Diagno	ted Re	emoval :272-2	ble Nitir 78 (199	nol St 95).	ent:
	C1	10		of Intravascular	Stents with Genetically Engir						
	C1	11	Eigler et al., Local Art Distribution, and Bioa	erial Wall Drug De ctivity of Forskolin	elivery from a Polymer Coate , JACC, 4A (701-1), Abstrac	d Remova t (Feb. 199	ble M 94).	etallic	Stent: F	Kineti	cs,
	C1		Gravlee, Heparin-Coated Cardiopulmonary Bypass Circuits, Journal of Cardiothoracic and Vascular Anesthesia, Vol. 8, No. 2, pp. 213-222 (1994).								
	C1	13	Helmus, <i>Medical Dev</i> SAMPE Technical Co	ice Design. A Sys inference, Nov. 6-	stems Approach: Central Ver 8, 1990.	nous Cath	eteres	, 22 <sup>nd</sup> I	Internat	ional	
	C1	C14 Helmus, Overview of Biomedical Materials, MRS Bulletin, pp. 33-38 (Sept. 1991).									
	C1		Herdeg et al., <i>Antipro</i> 3:197-199 (1998).	liferative Stent Co	atings: Taxol and Related Co	ompounds	, Sem	in. Inte	ervent. (	Cardi	ol.
	C1		Hubbell, <i>Pharmacolo</i> ։ 127S (1993).	gic Modification of	Materials, Cardiovascular Pa	athology, \	/ol. 2,	No. 3	(Suppl.	), 12	1S-
	C1	17	Inoue et al., An AB bl delivery of hydrophob	ock copolymer of ic drugs, Journal	oligo(methyl methacrylate) a of Controlled Release 51:22	nd poly(ad 1-229 (199	rylic a 18).	cid) fo	r micell	ar	
	C1		Kataoka et al., <i>Block</i> 24:119-132 (1993).	copolymer micelle	s as vehicles for drug delive	ry, Journa	of Co	ontrolle	d Relea	ase	
	C1	19	Levy et al., Strategies Biotechnol. Bioact. Po	For Treating Arte	nial Restenosis Using Polym Chem. Soc. Symp.], pp. 259-	eric Contr 268 (1994	olled I ).	Releas	e Impla	nts,	
IS	K/ C2		Liu et al., <i>Drug releas</i> 68:167-174 (2000).	e characteristics (	of unimolecular polymeric mi	celles, Jou	rnal o	f Cont	rolled R	teleas	se 

/SK/	C21	Marconi et al., Covalent bonding of heparin to a vinyl copolymer for biomedical applications, Biomaterials
ION		18(12):885-890 (1997).
	C22	Matsumaru et al., Embolic Materials For Endovascular Treatment of Cerebral Lesions, J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
	C23	Miyazaki et al., Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
	C24	Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
	C25	Nordrehaug et al., A novel biocompatible coating applied to coronary stents, European Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).
	C26	Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, American Heart Journal 136(6):1081-1087 (Dec. 1998)
	C27	Ozaki et al., New Stent Technologies, Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
	C28	Pechar et al., Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).
	C29	Peng et al., Role of polymers in improving the results of stenting in coronary arteries, Biomaterials 17:685-694 (1996).
	C30	Shigeno, Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor, Chemical Abstract 125:212307 (1996).
	C31	van Beusekom et al., Coronary stent coatings, Coronary Artery Disease 5(7):590-596 (July 1994).
	C32	Wilensky et al., Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries, Trends Cardiovasc. Med. 3(5):163-170 (1993).
/SK/	C33	Yokoyama et al., Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor; Journal of Controlled Release 50:79-92 (1998).
KAMINER	/S	haron Kennedy/ DATE CONSIDERED 12/21/2007
CAMINER: In	itial if re	ferences considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.
clude copy of	this form	n with next communication to applicant.